Immune cells engineered to fight pancreatic cancer enter first human test
NCT ID NCT07425483
First seen Feb 24, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This early-phase study tests a new treatment called CAR-NK cells (CL-NK-003) in 9 people with advanced pancreatic cancer that has not responded to standard therapies. The treatment uses specially modified immune cells to target and attack cancer cells. The main goals are to check safety and find the right dose, while also monitoring how well it controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.